Improved Phenotype-Based Definition for Identifying Carbapenemase Producers among Carbapenem-Resistant Enterobacteriaceae - Volume 21, Number 9—September 2015 - Emerging Infectious Disease journal - CDC
Volume 21, Number 9—September 2015
Emerging Infections Program
Emerging Infections Program
Improved Phenotype-Based Definition for Identifying Carbapenemase Producers among Carbapenem-Resistant Enterobacteriaceae
Multidrug-resistant organisms are a major public health concern worldwide (1–4). Of particular concern has been the emergence of resistance to carbapenem antimicrobial drugs among Enterobacteriaceae (4,5). In the United States, the reported percentage of common health care–associated infections caused by carbapenem-nonsusceptible Enterobacteriaceae increased from 1.2% in 2001 to 4.2% in 2011 (4), and the greatest increase (≈10%) occurred among Klebsiella species (4).
Although carbapenem nonsusceptibility among Enterobacteriaceae can result from several mechanisms, much of the recent increase in carbapenem-resistant Enterobacteriaceae (CRE) in the United States is likely due to the spread of carbapenemase-producing strains, particularly Klebsiella species that produce Klebsiella pneumoniae carbapenemase (KPC) (3,4). In addition to KPC, several other carbapenemases have been identified in the United States: New Delhi metallo-β-lactamase (NDM), oxacillinase (OXA), Verona integron–encoded metallo-β-lactamase (VIM), and imipenemase (IMP) (5,6). These enzymes are encoded by mobile genetic elements that have the potential to spread between bacterial species. The uptake of these elements among different bacterial species could result in further increases in the prevalence of carbapenem-resistant or panresistant bacteria, or both, and if this occurs, treatment options in the United States would be limited (7). Since 2006, the Centers for Disease Control and Prevention (CDC) has identified >100 NDM-producing CRE in the United States, including those that caused 2 hospital-based outbreaks (8,9). In light of the elements described above, much of the effort to prevent further spread of CRE has targeted carbapenemase-producing CRE. However, these efforts have been hampered because many clinical laboratories do not routinely perform CRE resistance-mechanism testing, so they cannot differentiate carbapenemase-producing CRE from CRE that are carbapenem-nonsusceptible due to other mechanisms. In addition, resistance-mechanism testing is also not routinely recommended for clinical purposes by the Clinical and Laboratory Standards Institute (CLSI) (10).
A phenotype-based CRE definition (i.e., based on antimicrobial drug susceptibility pattern) that is specific for carbapenemase-producing strains has the potential to facilitate CRE prevention by allowing health care facilities to target these strains for the most aggressive interventions without the need to rely on resistance-mechanism testing. The pre-2015 CDC CRE surveillance definition—nonsusceptiblity to imipenem, meropenem, or doripenem, and resistance to all third-generation cephalosporins tested, as determined by using CLSI M100-S23 testing standards (11)—was originally designed to preferentially identify carbapenemase-producing CRE (9). However, because of the number of antimicrobial drugs included and the complexity of the third-generation cephalosporin restriction (resistance to all tested), this phenotype-based definition proved to be complicated and difficult to implement by health care facilities for both surveillance and infection control efforts. In addition, use of this definition led to the mistaken assumption that CRE that did not meet the definition did not warrant any additional infection control precautions beyond standard precautions (9).
The objective of this analysis was to identify a phenotype-based definition that accurately differentiates carbapenemase-producing CRE from non–carbapenemase-producing CRE on the basis of antimicrobial susceptibility patterns. To achieve this, we evaluated isolates collected through CDC’s Emerging Infections Program (EIP) CRE surveillance system (http://www.cdc.gov/hai/eip/mugsi.html).
Dr. Chea is an Epidemic Intelligence Service officer with the Division of Healthcare Quality Promotion at the CDC, Atlanta. His primary research interest is healthcare-associated infections.
We thank Kamile Rasheed and David Lonsway for their advice and Christine Lascols for confirmatory testing at CDC.
- Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:155–64.
- Smolinski MS, Hamburg MA, Lederberg J. Microbial threats to health: emergence, detection, and response. Washington: The National Academies Press; 2003.
- Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011;53:60–7.
- Centers for Disease Control and Prevention. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep.2013;62:165–70 .
- Lee CS, Vasoo S, Hu F, Patel R, Doia Y. Klebsiella pneumoniae ST147 coproducing NDM-7 carbapenemase and RmtF 16S rRNA methyltransferase in Minnesota. J Clin Microbiol. 2014;52:4109–10.
- Mathers AJ, Hazen KC, Carroll J, Yeh AJ, Cox HL, Bonomo RA, First clinical cases of OXA-48-producing carbapenem-resistant Klebsiella pneumoniaein the United States: the “menace” arrives in the new world. J Clin Microbiol. 2013;51:680–3.
- Centers for Disease Control and Prevention. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep. 2009;58:256–60 .
- Epstein L, Hunter JC, Arwady MA, Tsai V, Stein L, Gribogiannis M, New Delhi metallo-β-lactamase–producing carbapenem-resistant Escherichia coliassociated with exposure to duodenoscopes. JAMA. 2014;312:1447–55.
- Epson EE, Pisney LM, Wendt JM, MacCannell DR, Janelle SJ, Kitchel B, Carbapenem-resistant Klebsiella pneumoniae producing New Delhi metallo-β-lactamase at an acute care hospital, Colorado, 2012. Infect Control Hosp Epidemiol. 2014;35:390–7.
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-fourth informational supplement. M100-S24. Wayne (PA): The Institute; 2014.
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement. M100-S23. Wayne (PA): The Institute; 2013.
- Rasheed JK, Kitchel B, Zhu W, Anderson KF, Clark NC, Ferraro MJ, New Delhi metallo-β-lactamase–producing Enterobacteriaceae, United States.Emerg Infect Dis. 2013;19:870–8.
- Nordmann P, Poirel L. Strategies for identification of carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2013;68:487–9.
- Tijet N, Boyd D, Patel SN, Mulvey MR, Melano RG. Evaluation of the Carba NP test for rapid detection of carbapenemase-producingEnterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013;57:4578–80.
- Voulgari E, Poulou A, Koumaki V, Tsakris A. Carbapenemase-producing Enterobacteriaceae: now that the storm is finally here, how will timely detection help us fight back? Future Microbiol. 2013;8:27–39.
- Nordmann P, Poirel L, Dortet L. Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2012;18:1503–7.
Suggested citation for this article: Chea N, Bulens SN, Kongphet-Tran T, Lynfield R, Shaw KM, Vagnone PS, et al. Improved phenotype-based definition for identifying carbapenemase producers among carbapenem-resistant Enterobacteriaceae. Emerg Infect Dis. 2015 Sep [date cited].http://dx.doi.org/10.3201/eid2109.150198